<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>526</serviceExecutionTime><Drug id="40735"><DrugName>dovitinib</DrugName><DrugNamesKey><Name id="42866677">dovitinib</Name><Name id="42871237">dovitinib lactate (USAN)</Name></DrugNamesKey><DrugSynonyms><Name><Value>GFKI-258</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>GFKI, Chiron</Value></Name><Name><Value>VEGFR kinase inhibitor, Chiron</Value></Name><Name><Value>growth factor kinase inhibitor, Chiron</Value></Name><Name><Value>VEGF receptor kinase inhibitor (cancer), Chiron</Value></Name><Name><Value>VEGF/FGF/PDGF receptor kinase inhibitor, Chiron</Value></Name><Name><Value>VEGFR kinase inhibitor, Novartis</Value></Name><Name><Value>VEGF receptor kinase inhibitor (cancer), Novartis</Value></Name><Name><Value>growth factor kinase inhibitor, Novartis</Value></Name><Name><Value>VEGF/FGF/PDGF receptor kinase inhibitor, Novartis</Value></Name><Name><Value>GFKI, Novartis</Value></Name><Name><Value>TKI-258</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>dovitinib</Value><Types><Type>INN</Type></Types></Name><Name><Value>dovitinib lactate (USAN)</Value><Types><Type>USAN</Type></Types></Name><Name><Value>CHIR-258</Value></Name><Name><Value>dovitinib lactate</Value></Name><Name><Value>TK-1258</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>405169-16-6</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>915769-50-5</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>692737-80-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="15385">Chiron Corp</CompanyOriginator><CompaniesPrimary><Company id="1143038">OV-SPV2 ApS</Company></CompaniesPrimary><CompaniesSecondary><Company id="15385">Chiron Corp</Company><Company id="23137">Novartis AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="40735" type="Drug"><TargetEntity id="343725" type="siDrug">Dovitinib lactate</TargetEntity></SourceEntity><SourceEntity id="1143038" type="Company"><TargetEntity id="5070506204" type="organizationId">Ov-Spv2 ApS</TargetEntity></SourceEntity><SourceEntity id="15385" type="Company"><TargetEntity id="5036161975" type="organizationId">Chiron Corp</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="1240" type="ciIndication"><TargetEntity id="C45" type="ICD10"></TargetEntity><TargetEntity id="163" type="ICD9"></TargetEntity><TargetEntity id="10027406" type="MEDDRA"></TargetEntity><TargetEntity id="D008654" type="MeSH"></TargetEntity><TargetEntity id="50251" type="ORPHANET"></TargetEntity><TargetEntity id="-666440137" type="omicsDisease"></TargetEntity><TargetEntity id="2015" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"></TargetEntity><TargetEntity id="D002289" type="MeSH"></TargetEntity><TargetEntity id="-1730468577" type="omicsDisease"></TargetEntity><TargetEntity id="612" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1612" type="ciIndication"><TargetEntity id="10047716" type="MEDDRA"></TargetEntity><TargetEntity id="D006623" type="MeSH"></TargetEntity><TargetEntity id="892" type="ORPHANET"></TargetEntity><TargetEntity id="-121001688" type="omicsDisease"></TargetEntity><TargetEntity id="1519" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1648" type="ciIndication"><TargetEntity id="10001388" type="MEDDRA"></TargetEntity><TargetEntity id="D018268" type="MeSH"></TargetEntity><TargetEntity id="-1334960598" type="omicsDisease"></TargetEntity><TargetEntity id="1336" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1705" type="ciIndication"><TargetEntity id="10014733" type="MEDDRA"></TargetEntity><TargetEntity id="D016889" type="MeSH"></TargetEntity><TargetEntity id="-49801714" type="omicsDisease"></TargetEntity><TargetEntity id="597" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1731" type="ciIndication"><TargetEntity id="D015470" type="MeSH"></TargetEntity><TargetEntity id="519" type="ORPHANET"></TargetEntity><TargetEntity id="-1550871001" type="omicsDisease"></TargetEntity><TargetEntity id="686" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1766" type="ciIndication"><TargetEntity id="10067946" type="MEDDRA"></TargetEntity><TargetEntity id="D002292" type="MeSH"></TargetEntity><TargetEntity id="-994324469" type="omicsDisease"></TargetEntity><TargetEntity id="609" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"></TargetEntity><TargetEntity id="88673" type="ORPHANET"></TargetEntity><TargetEntity id="-1116061312" type="omicsDisease"></TargetEntity><TargetEntity id="1973" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"></TargetEntity><TargetEntity id="10028228" type="MEDDRA"></TargetEntity><TargetEntity id="D009101" type="MeSH"></TargetEntity><TargetEntity id="29073" type="ORPHANET"></TargetEntity><TargetEntity id="-18870694" type="omicsDisease"></TargetEntity><TargetEntity id="710" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="202" type="ciIndication"><TargetEntity id="C22" type="ICD10"></TargetEntity><TargetEntity id="10019695" type="MEDDRA"></TargetEntity><TargetEntity id="D008113" type="MeSH"></TargetEntity><TargetEntity id="-897418746" type="omicsDisease"></TargetEntity><TargetEntity id="610" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2054" type="ciIndication"><TargetEntity id="10066476" type="MEDDRA"></TargetEntity><TargetEntity id="D019337" type="MeSH"></TargetEntity><TargetEntity id="-105358819" type="omicsDisease"></TargetEntity><TargetEntity id="1328" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2380" type="ciIndication"><TargetEntity id="C67" type="ICD10"></TargetEntity><TargetEntity id="188.9" type="ICD9"></TargetEntity><TargetEntity id="10005003" type="MEDDRA"></TargetEntity><TargetEntity id="-2101107804" type="omicsDisease"></TargetEntity><TargetEntity id="578" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2454" type="ciIndication"><TargetEntity id="10018336" type="MEDDRA"></TargetEntity><TargetEntity id="D005909" type="MeSH"></TargetEntity><TargetEntity id="360" type="ORPHANET"></TargetEntity><TargetEntity id="-1357419475" type="omicsDisease"></TargetEntity><TargetEntity id="678" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3205" type="ciIndication"><TargetEntity id="10051066" type="MEDDRA"></TargetEntity><TargetEntity id="D046152" type="MeSH"></TargetEntity><TargetEntity id="44890" type="ORPHANET"></TargetEntity><TargetEntity id="-1743085733" type="omicsDisease"></TargetEntity><TargetEntity id="668" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3257" type="ciIndication"><TargetEntity id="10027480" type="MEDDRA"></TargetEntity><TargetEntity id="708" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"></TargetEntity><TargetEntity id="589" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3666" type="ciIndication"><TargetEntity id="10063916" type="MEDDRA"></TargetEntity><TargetEntity id="647" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3948" type="ciIndication"><TargetEntity id="10021980" type="MEDDRA"></TargetEntity><TargetEntity id="D058922" type="MeSH"></TargetEntity><TargetEntity id="-458734496" type="omicsDisease"></TargetEntity><TargetEntity id="2303" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="4250" type="ciIndication"><TargetEntity id="10050513" type="MEDDRA"></TargetEntity><TargetEntity id="3229" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="989" type="ciIndication"><TargetEntity id="10061451" type="MEDDRA"></TargetEntity><TargetEntity id="D015179" type="MeSH"></TargetEntity><TargetEntity id="-1280257855" type="omicsDisease"></TargetEntity><TargetEntity id="594" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3154" type="Action"><TargetEntity id="4836" type="Mechanism">Anti-Colony Stimulating Factor 1 Receptor (CSF1R)</TargetEntity><TargetEntity id="2314" type="Mechanism">CSF1R (c-FMS) Inhibitors</TargetEntity><TargetEntity id="4956" type="Mechanism">Anti-M-CSF</TargetEntity></SourceEntity><SourceEntity id="3806" type="Action"><TargetEntity id="1910" type="Mechanism">Anti-CD135 (flt-3)</TargetEntity><TargetEntity id="1628" type="Mechanism">Flt3 (FLK2/STK1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3808" type="Action"><TargetEntity id="1704" type="Mechanism">KIT (C-KIT) Inhibitors</TargetEntity><TargetEntity id="3405" type="Mechanism">Anti-c-KIT</TargetEntity><TargetEntity id="5665" type="Mechanism">KIT (C-KIT) (Asp816Val Mutant) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="948" type="Action"><TargetEntity id="1072" type="Mechanism">PDGFR Family Inhibitors</TargetEntity><TargetEntity id="1789" type="Mechanism">Platelet-Derived Growth Factor (PDGF) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3682" type="Action"><TargetEntity id="2298" type="Mechanism">FGFR1 Inhibitors</TargetEntity><TargetEntity id="4080" type="Mechanism">Anti-FGFR1</TargetEntity></SourceEntity><SourceEntity id="3688" type="Action"><TargetEntity id="3639" type="Mechanism">Anti-FGFR3</TargetEntity><TargetEntity id="1702" type="Mechanism">FGFR3 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3840" type="Action"><TargetEntity id="2352" type="Mechanism">High Affinity Nerve Growth Factor Receptor (TrKA) Inhibitors</TargetEntity><TargetEntity id="4831" type="Mechanism">Anti-High Affinity Nerve Growth Factor Receptor (TrKA)</TargetEntity></SourceEntity><SourceEntity id="3848" type="Action"><TargetEntity id="1786" type="Mechanism">Anti-VEGFR-2 (KDR)</TargetEntity><TargetEntity id="1309" type="Mechanism">VEGFR-2 (FLK-1/KDR) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3818" type="Action"><TargetEntity id="7214" type="Mechanism">Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret (RET; CDHF12; PTC) Activators</TargetEntity><TargetEntity id="1922" type="Mechanism">RET Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3846" type="Action"><TargetEntity id="2609" type="Mechanism">Anti-VEGFR-1 (Flt-1)</TargetEntity><TargetEntity id="1308" type="Mechanism">VEGFR-1 (Flt-1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3685" type="Action"><TargetEntity id="4378" type="Mechanism">Anti-FGFR2</TargetEntity><TargetEntity id="2243" type="Mechanism">FGFR2 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3850" type="Action"><TargetEntity id="2518" type="Mechanism">Anti-VEGFR-3 (FLT4)</TargetEntity><TargetEntity id="1627" type="Mechanism">VEGFR-3 (FLT4) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="61" type="Action"><TargetEntity id="885" type="Mechanism">Angiogenesis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00510" type="ciTarget"><TargetEntity id="174052253714363" type="siTarget">Macrophage colony-stimulating factor 1 receptor</TargetEntity><TargetEntity id="471" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00736" type="ciTarget"><TargetEntity id="205697481622603" type="siTarget">Fibroblast growth factor receptor 1</TargetEntity><TargetEntity id="261" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00737" type="ciTarget"><TargetEntity id="170054004822633" type="siTarget">Fibroblast growth factor receptor 2</TargetEntity><TargetEntity id="2824" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00738" type="ciTarget"><TargetEntity id="360872222613" type="siTarget">Fibroblast growth factor receptor 3</TargetEntity><TargetEntity id="262" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00762" type="ciTarget"><TargetEntity id="212861059123223" type="siTarget">Receptor-type tyrosine-protein kinase FLT3</TargetEntity><TargetEntity id="7001" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01208" type="ciTarget"><TargetEntity id="87400752538153" type="siTarget">Mast/stem cell growth factor receptor Kit</TargetEntity><TargetEntity id="441" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01670" type="ciTarget"><TargetEntity id="24642065259793" type="siTarget">Proto-oncogene tyrosine-protein kinase receptor Ret</TargetEntity><TargetEntity id="683" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01891" type="ciTarget"><TargetEntity id="113262568449143" type="siTarget">High affinity nerve growth factor receptor</TargetEntity><TargetEntity id="788" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01938" type="ciTarget"><TargetEntity id="62129556823213" type="siTarget">Vascular endothelial growth factor receptor 1</TargetEntity><TargetEntity id="810" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01939" type="ciTarget"><TargetEntity id="172853942537913" type="siTarget">Vascular endothelial growth factor receptor 2</TargetEntity><TargetEntity id="811" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01940" type="ciTarget"><TargetEntity id="108789232923243" type="siTarget">Vascular endothelial growth factor receptor 3</TargetEntity><TargetEntity id="812" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-03992" type="ciTarget"><TargetEntity id="23230" type="siTarget">Fms-related tyrosine kinase 3 ligand</TargetEntity><TargetEntity id="7000" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1705">Endometrioid carcinoma</Indication><Indication id="1766">Renal cell carcinoma</Indication><Indication id="1767">Hepatocellular carcinoma</Indication><Indication id="202">Liver tumor</Indication><Indication id="3205">Gastrointestinal stromal tumor</Indication><Indication id="49">Breast tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1240">Mesothelioma</Indication><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="1612">Hippel Lindau syndrome</Indication><Indication id="1648">Adrenal cortical carcinoma</Indication><Indication id="1731">Acute myelogenous leukemia</Indication><Indication id="1828">Multiple myeloma</Indication><Indication id="2054">Hematological neoplasm</Indication><Indication id="2380">Bladder cancer</Indication><Indication id="2454">Glioblastoma</Indication><Indication id="3153">Adenoid tumor</Indication><Indication id="3246">Hormone refractory prostate cancer</Indication><Indication id="3257">Stage IV melanoma</Indication><Indication id="3657">Metastatic breast cancer</Indication><Indication id="3666">Metastatic stomach cancer</Indication><Indication id="3713">Advanced solid tumor</Indication><Indication id="3948">Inflammatory breast cancer</Indication><Indication id="4250">Metastatic renal cell carcinoma</Indication><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication><Indication id="989">Colorectal tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="3808">Kit tyrosine kinase inhibitor</Action><Action id="3850">VEGF-3 receptor antagonist</Action><Action id="3848">VEGF-2 receptor antagonist</Action><Action id="3846">VEGF-1 receptor antagonist</Action><Action id="3840">TrkA receptor antagonist</Action><Action id="3818">Ret tyrosine kinase receptor inhibitor</Action><Action id="3154">CSF-1 antagonist</Action><Action id="3688">FGF3 receptor antagonist</Action><Action id="3685">FGF2 receptor antagonist</Action><Action id="3682">FGF1 receptor antagonist</Action><Action id="3806">Flt3 tyrosine kinase inhibitor</Action><Action id="15591">SL cytokine ligand inhibitor</Action><Action id="948">PDGF receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="61">Angiogenesis inhibitor</Action><Action id="62255">Anticancer protein kinase inhibitor</Action><Action id="695">Metastasis inhibitor</Action></ActionsSecondary><Technologies><Technology id="1263">Immuno-oncology</Technology><Technology id="585">Oral formulation</Technology><Technology id="586">Capsule formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-30T10:42:58.000Z</LastModificationDate><ChangeDateLast>2019-07-01T00:00:00.000Z</ChangeDateLast><AddedDate>2002-07-22T13:21:20.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1143038" linkType="Company"&gt;OV-SPV2&lt;/ulink&gt; (a spin-out and majority-owned subsidiary of &lt;ulink linkID="1095288" linkType="Company"&gt;Oncology Venture&lt;/ulink&gt; ), under license from &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt;, is developing dovitinib, a potent FGFR-1, -2, -3, VEGFR-1, -2, -3 , PDGFR, KIT, RET, TrkA, colony stimulating factor 1 receptor, and fms-like tyrosine kinase 3 inhibitor,  for the potential oral treatment of renal, liver and breast cancer  [&lt;ulink linkID="783234" linkType="Reference"&gt;783234&lt;/ulink&gt;], [&lt;ulink linkID="1175230" linkType="Reference"&gt;1175230&lt;/ulink&gt;], [&lt;ulink linkID="1325903" linkType="Reference"&gt;1325903&lt;/ulink&gt;], [&lt;ulink linkID="1897072" linkType="Reference"&gt;1897072&lt;/ulink&gt;], [&lt;ulink linkID="1946763" linkType="Reference"&gt;1946763&lt;/ulink&gt;], [&lt;ulink linkID="1973624" linkType="Reference"&gt;1973624&lt;/ulink&gt;], [&lt;ulink linkID="1997350" linkType="Reference"&gt;1997350&lt;/ulink&gt;], [&lt;ulink linkID="1997937" linkType="Reference"&gt;1997937&lt;/ulink&gt;], [&lt;ulink linkID="2020644" linkType="Reference"&gt;2020644&lt;/ulink&gt;], [&lt;ulink linkID="2164143" linkType="Reference"&gt;2164143&lt;/ulink&gt;]. In January 2018, data from the Drug Response Prediction (DRP) test performed on phase III data assessing dovitinib  in renal cancer were reported  [&lt;ulink linkID="1997350" linkType="Reference"&gt;1997350&lt;/ulink&gt;].  In July 2018, a   phase III   pivotal trial for liver cancer was underway [&lt;ulink linkID="2057182" linkType="Reference"&gt;2057182&lt;/ulink&gt;]. In April 2019, data from DRP testing in a phase II trial for breast  cancer were reported  [&lt;ulink linkID="2146834" linkType="Reference"&gt;2146834&lt;/ulink&gt;]. In April 2019, positive data were reported from the both a dovitinib DRP biomarker and a combination biomarker PD1-PD-L1/Dovitinib DRP. At that time, the company confirmed supplemental NDA(sNDA) submission for marketing approval of dovitinib based on existing Novartis data in renal cancer [&lt;ulink linkID="2137579" linkType="Reference"&gt;2137579&lt;/ulink&gt;]. In July 2018, Oncology Venture was planning to analyze the large amount of data from adenoid cystic carcinoma (AdCC) patients to refine the dovitinib DRP biomarker to hone its predictive ability to identify high likelihood responders for dovitinib  [&lt;ulink linkID="2049943" linkType="Reference"&gt;2049943&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Novartis (formerly &lt;ulink linkID="15385" linkType="Company"&gt;Chiron&lt;/ulink&gt;) was developing dovitinib (TKI-258; TK-1258; GFKI-258; formerly CHIR-258), a potent FGFR-1, -2, -3, VEGFR-1, -2, -3 , PDGFR, KIT, RET, TrkA, colony stimulating factor 1 receptor, and fms-like tyrosine kinase 3 inhibitor, for the potential oral treatment of various solid tumors and multiple myeloma [&lt;ulink linkID="413050" linkType="reference"&gt;413050&lt;/ulink&gt;], [&lt;ulink linkID="485989" linkType="reference"&gt;485989&lt;/ulink&gt;], [&lt;ulink linkID="486163" linkType="reference"&gt;486163&lt;/ulink&gt;], [&lt;ulink linkID="783234" linkType="Reference"&gt;783234&lt;/ulink&gt;], [&lt;ulink linkID="1175230" linkType="Reference"&gt;1175230&lt;/ulink&gt;], [&lt;ulink linkID="1325903" linkType="Reference"&gt;1325903&lt;/ulink&gt;].  However, in January 2015, Novartis noted that development was discontinued [&lt;ulink linkID="1636427" linkType="Reference"&gt;1636427&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2009, a phase II trial in breast cancer began [&lt;ulink linkID="1129303" linkType="Reference"&gt;1129303&lt;/ulink&gt;]; in June 2011, data were presented [&lt;ulink linkID="1194090" linkType="Reference"&gt;1194090&lt;/ulink&gt;]. In January 2012, a phase II study  was initiated in the US in patients with inflammatory breast cancer. The trial was expected to complete in January 2016  [&lt;ulink linkID="1441754" linkType="Reference"&gt;1441754&lt;/ulink&gt;]; in December 2014, data were presented [&lt;ulink linkID="1616497" linkType="Reference"&gt;1616497&lt;/ulink&gt;]. In April 2010, a phase II prostate cancer trial began [&lt;ulink linkID="1129284" linkType="Reference"&gt;1129284&lt;/ulink&gt;]. In March 2010, a phase II bladder cancer trial began [&lt;ulink linkID="1129310" linkType="Reference"&gt;1129310&lt;/ulink&gt;]. In May 2010, a phase II  multiple myeloma trial was initiated, which was ongoing in December 2012  [&lt;ulink linkID="1178898" linkType="Reference"&gt;1178898&lt;/ulink&gt;]. In August 2011, a phase II hepatocellular carcinoma trial began [&lt;ulink linkID="1230990" linkType="Reference"&gt;1230990&lt;/ulink&gt;], [&lt;ulink linkID="1178464" linkType="Reference"&gt;1178464&lt;/ulink&gt;];  in January 2013, the trial was initiated in China  [&lt;ulink linkID="1178464" linkType="Reference"&gt;1178464&lt;/ulink&gt;], [&lt;ulink linkID="1384043" linkType="Reference"&gt;1384043&lt;/ulink&gt;], [&lt;ulink linkID="1385085" linkType="Reference"&gt;1385085&lt;/ulink&gt;]. In June 2011, a phase II endometrial cancer trial was initiated [&lt;ulink linkID="1230990" linkType="Reference"&gt;1230990&lt;/ulink&gt;]; in September 2014, data were presented  [&lt;ulink linkID="1596297" linkType="Reference"&gt;1596297&lt;/ulink&gt;]. In March 2012, a phase II adenoid cancer trial was initiated [&lt;ulink linkID="1261087" linkType="Reference"&gt;1261087&lt;/ulink&gt;].  In September 2009, a phase I/II trial in advanced melanoma had been completed [&lt;ulink linkID="1263821" linkType="Reference"&gt;1263821&lt;/ulink&gt;]. In November 2011, a phase I advanced solid tumor trial began in Japan [&lt;ulink linkID="1241286" linkType="Reference"&gt;1241286&lt;/ulink&gt;].     In May 2012, a phase II trial in patients with  gastrointestinal stromal tumors (GIST) was initiated [&lt;ulink linkID="1243285" linkType="Reference"&gt;1243285&lt;/ulink&gt;]. A phase II trial in von Hippel-Lindau syndrome began in November 2012 [&lt;ulink linkID="1178215" linkType="Reference"&gt;1178215&lt;/ulink&gt;]. In August  2011, a   phase II study was initiated in patients with advanced hepatocellular carcinoma  [&lt;ulink linkID="1178464" linkType="Reference"&gt;1178464&lt;/ulink&gt;]. In October 2012, a phase II trial was initiated in Korea in patients with  metastatic or unresectable gastric cancer.  The trial was expected to complete in March 2014 [&lt;ulink linkID="1442057" linkType="Reference"&gt;1442057&lt;/ulink&gt;]. In January 2014, the company planned to submit regulatory filings in the US in 2017 [&lt;ulink linkID="1519399" linkType="Reference"&gt;1519399&lt;/ulink&gt;]. In January 2013, a phase II trial  was expected to begin in Canada in March 2013, in patients  with advanced malignant pleural mesothelioma. At that time, the trial was estimated to complete in June 2016 [&lt;ulink linkID="1439473" linkType="Reference"&gt;1439473&lt;/ulink&gt;]. In February 2013, a phase II trial for NSCLC and colorectal cancer was initiated. At that time, the trial was expected to complete in October 2016 [&lt;ulink linkID="1440754" linkType="Reference"&gt;1440754&lt;/ulink&gt;]. In December 2011, a phase II trial for adrenocortical carcinoma was initiated [&lt;ulink linkID="1442637" linkType="Reference"&gt;1442637&lt;/ulink&gt;]; in June 2014, data were presented [&lt;ulink linkID="1562828" linkType="Reference"&gt;1562828&lt;/ulink&gt;]. In December 2012, a phase II trial was initiated in the US for glioblastoma [&lt;ulink linkID="1448594" linkType="Reference"&gt;1448594&lt;/ulink&gt;]. However, in January 2015, Novartis noted that development was discontinued [&lt;ulink linkID="1636427" linkType="Reference"&gt;1636427&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Novartis was previously  developing the drug for other indications. In March 2011, a phase III trial in metastatic renal cell carcinoma (RCC) was initiated [&lt;ulink linkID="1178876" linkType="Reference"&gt;1178876&lt;/ulink&gt;]. In January 2013, filing for RCC was expected later that year [&lt;ulink linkID="1388709" linkType="Reference"&gt;1388709&lt;/ulink&gt;]. In July 2013, however, the company reported that the trial did not meet the primary endpoint of progression-free survival compared with &lt;ulink linkID="29831" linkType="Drug"&gt;sorafenib&lt;/ulink&gt; in patients with mRCC after failure with prior therapies [&lt;ulink linkID="1453845" linkType="Reference"&gt;1453845&lt;/ulink&gt;]; no plans for further development in RCC were reported. By October 2013, the company's Japanese development pipeline no longer listed dovitinib for RCC [&lt;ulink linkID="1494129" linkType="Reference"&gt;1494129&lt;/ulink&gt;]. A phase I trial was initiated in acute myelogenous leukemia (AML) in September 2004 [&lt;ulink linkID="1353100" linkType="Reference"&gt;1353100&lt;/ulink&gt;], with a second phase I trial in AML beginning a month later [&lt;ulink linkID="565808" linkType="Reference"&gt;565808&lt;/ulink&gt;], however no further development was reported for this indication.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In April 2019, the company confirmed the submission of sNDA to the US FDA, for marketing approval of dovitinib based on existing Novartis data in renal cancer [&lt;ulink linkID="2137579" linkType="Reference"&gt;2137579&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2013, filings for solid tumors were expected in 2016 [&lt;ulink linkID="1388709" linkType="Reference"&gt;1388709&lt;/ulink&gt;]. In January 2014, the company planned to submit regulatory applications in 2017 [&lt;ulink linkID="1519399" linkType="Reference"&gt;1519399&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, the US FDA granted dovitinib Orphan designation for the treatment of adenoid cystic carcinoma [&lt;ulink linkID="1483437" linkType="Reference"&gt;1483437&lt;/ulink&gt;]. In June 2018, the US FDA had transferred the dovitinib orphan drug designation for the treatment of adenoid cystic carcinoma  from Novartis  to Oncology Venture [&lt;ulink linkID="2049943" linkType="Reference"&gt;2049943&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By April 2019, data had showed that dovitinib DRP identified best responders based on patient biopsies from clinical trials in endometrial and GIST cancer [&lt;ulink linkID="2146834" linkType="Reference"&gt;2146834&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2019, positive data were reported from the both a dovitinib DRP biomarker and a combination biomarker PD1-PD-L1/Dovitinib DRP. Data  had shown highly efficacy similar to dovitinib on using dovitinib in combination with &lt;ulink linkID="45841" linkType="Drug"&gt;Lenvima&lt;/ulink&gt; + &lt;ulink linkID="70667" linkType="Drug"&gt;Keytruda&lt;/ulink&gt; ((PD-L1/ PD1 inhibitors). At that time, the biostatistical analysis of the dovitinib clinical data in renal cancer confirms the direct application of NDA for approval  [&lt;ulink linkID="2137579" linkType="Reference"&gt;2137579&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2018, OV-SPV2 expected to initiate a phase II of dovitinib in patients with breast and liver cancer. The company would refine the dovitinib DRP biomarker and would use it  to prospectively select patients most likely to respond to the drug for inclusion in the planned trial [&lt;ulink linkID="2020644" linkType="Reference"&gt;2020644&lt;/ulink&gt;]. In April 2019, data showed good predictability with dovitinib DRP in patients with breast and liver cancer [&lt;ulink linkID="2146834" linkType="Reference"&gt;2146834&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2017, the company planned to request FDA for an End-Of-Phase II meeting  [&lt;ulink linkID="1973624" linkType="Reference"&gt;1973624&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2017, OV-SPV2 planned a blinded, proof of concept, DRP test on the available data to assess whether  the DRP tool could identify responders from the clinical trials [&lt;ulink linkID="1897072" linkType="Reference"&gt;1897072&lt;/ulink&gt;]. By October 2017, OV-SPV2 had initiated the test, and at that time, data were expected in November/December 2017 [&lt;ulink linkID="1973624" linkType="Reference"&gt;1973624&lt;/ulink&gt;]. In January 2018, results comparing the DRP test performed in biopsies of renal patients with the outcomes of  the blinded phase III trial were reported to be consistent  [&lt;ulink linkID="1997350" linkType="Reference"&gt;1997350&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Renal cell carcinoma&lt;/subtitle&gt;In April 2018, further data were reported. In a phase III study of dovitinib in patients with  metastatic RCC, the drug showed therapeutic equivalence with &lt;ulink linkID="29831" linkType="Drug"&gt;sorafenib&lt;/ulink&gt;  [&lt;ulink linkID="2020644" linkType="Reference"&gt;2020644&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2011, an open-label, randomized, phase III trial  (&lt;ulink linkID="71328" linkType="Protocol"&gt;NCT01223027&lt;/ulink&gt;; CTKI258A2302; EudraCT 2009-015459-25) was initiated in the US, Canada and Germany to evaluate dovitinib versus sorafenib in patients (expected n = 550) with metastatic RCC after failure with prior therapies. At that time, primary completion was expected in May 2013 [&lt;ulink linkID="1178876" linkType="Reference"&gt;1178876&lt;/ulink&gt;]; in April 2013, the trial was ongoing [&lt;ulink linkID="1399932" linkType="Reference"&gt;1399932&lt;/ulink&gt;].  In July 2013, Novartis reported that the trial did not meet its primary endpoint of progression-free survival (PFS) [&lt;ulink linkID="1453845" linkType="Reference"&gt;1453845&lt;/ulink&gt;]. In October 2013, data were presented from the trial at the 2013 European Cancer Congress in Amsterdam, the Netherlands.  Data demonstrated that efficacy of dovitinib was not superior to sorafenib [&lt;ulink linkID="1480249" linkType="Reference"&gt;1480249&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2014, data were presented from a single-arm, single-site, phase II study (&lt;ulink linkID="110635" linkType="Protocol"&gt;DILIGENCE-1&lt;/ulink&gt;)  in 30 patients with first-line metastatic RCC at the 50th ASCO meeting in Chicago, IL. The median progression-free survival was found to be 6.2 months. Of the 28 patients evaluable, 29% of patients showed partial response, 53% of patients had stable disease and 18% of patients had progressive disease [&lt;ulink linkID="1562820" linkType="Reference"&gt;1562820&lt;/ulink&gt;]. In May 2015, further clinical data were presented from this study (ACTRN12612000140853) at the 51st ASCO meeting in Chicago, IL. The mean change in left ventricular ejection fraction was found to be -1.1% at week 12.  None of the patients suffered a clinical cardiac event nor symptoms. Overall, dovitinib showed sub-clinical cardiac effects, but not dissimilar to those observed with other anti-VEGFR tyrosine kinase inhibitors [&lt;ulink linkID="1661995" linkType="Reference"&gt;1661995&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2008, a phase I/II study (&lt;ulink linkID="40927" linkType="Protocol"&gt;NCT00715182&lt;/ulink&gt;; CTKI258A2107) began in the US, Europe and Taiwan in patients (n = 81) with advanced or metastatic RCC that was refractory to standard therapy. It was due to be completed in June 2010 [&lt;ulink linkID="1129301" linkType="Reference"&gt;1129301&lt;/ulink&gt;]. In 2009,  data were presented at the 45th ASCO meeting in Orlando, FL, showing that the drug was well tolerated, with some clinical benefit  [&lt;ulink linkID="1009364" linkType="Reference"&gt;1009364&lt;/ulink&gt;]. In June 2010, clinical data were presented at the 46th ASCO meeting in Chicago, IL, which showed a partial response (PR), stable disease (SD) and progressive disease (PD) was achieved by 2, 9 and 5 patients, respectively. Median progression-free survival was 5.5 months. In a subset of patients (n = 10) previously treated with VEGFR TK  and mTOR inhibitors, PR,   PD and SD was seen in 1,   1 and 7 patients, respectively. At that time, the phase II portion was ongoing and was expected to be completed by December 2010. [&lt;ulink linkID="1104928" linkType="Reference"&gt;1104928&lt;/ulink&gt;]. In June 2011, clinical data were presented at the 47th ASCO meeting in Chicago, IL. In 59 patients evaluable for safety, nausea, diarrhea, vomiting, decreased appetite, asthenia and fatigue were the most common adverse events observed. Of  the patients evaluable for efficacy (n = 51), the average duration of exposure was 89 days, with 51% of patients discontinuing due to progressive disease (PD).   The median progression-free survival  and overall survival   (OS) were 6.1 and 16 months, respectively. The study achieved its primary efficacy objective and, at that time,  an additional 30 patients were to be treated [&lt;ulink linkID="1196350" linkType="Reference"&gt;1196350&lt;/ulink&gt;].   The trial completed in July 2012 [&lt;ulink linkID="1129301" linkType="Reference"&gt;1129301&lt;/ulink&gt;]. In September 2013, further data from Asian and non-Asian patients (n = 57) were presented at the 2013 European Cancer Congress in Amsterdam, the Netherlands.  In both Asian and non-Asian population, the Cmax was reached within a median of 6 to 7 h. The  AUC and Cmax values decreased from day 1 to 15 by 18 and 33% and 16 and 20% for Asian and non-Asian populations, respectively [&lt;ulink linkID="1481448" linkType="Reference"&gt;1481448&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, data from a phase I pharmacokinetic study in metastatic RCC patients were presented at the 104th AACR Annual Meeting in Washington DC. Data demonstrate that the oral bioavailability was comparable between final market image and clinical service form capsule formulations of dovitinib. Clinically relevant effect of high-fat and low-fat meals was not observed on the bioavailability of dovitinib [&lt;ulink linkID="1399932" linkType="Reference"&gt;1399932&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, a phase Ib trial (&lt;ulink linkID="96043" linkType="Protocol"&gt;NCT01714765&lt;/ulink&gt;; DEVELOP) in patients with metastatic clear cell renal cancer began that was designed to assess the tolerability and early activity signal of dovitinib in combination with &lt;ulink linkID="13340" linkType="Drug"&gt;everolimus&lt;/ulink&gt;. The trial completed in October 2012 [&lt;ulink linkID="1523877" linkType="Reference"&gt;1523877&lt;/ulink&gt;]. In January 2014, data from the study were presented at the ASCO Genitourinary Cancers Symposium in San Francisco, CA. In the study up to four cohorts of three to six patients (3 + 3 design) would be treated with escalated doses of daily oral everolimus (5 to 10 mg po, qd) and dovitinib (200 to 500 mg po, 5/7 days). In total, 18 patients were recruited into the study and 15 patients received the MTD (5-mg everolimus qd + 200-mg dovitinib day 1 to 5/7). The combination was not tolerable at higher doses because of grade 3 fatigue and grade 3 nausea occurring in 2 of 3 and 1 of 3 patients within 1 month of therapy, respectively. At the MTD, the response rate was 7% (1 of 15 patients) and progression free survival was 7 months. It was concluded fatigue was the dose-limiting toxicity, and that the combination had modest efficacy but that it did not meet all of the planned efficacy endpoints [&lt;ulink linkID="1522196" linkType="Reference"&gt;1522196&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hematological cancers&lt;/subtitle&gt;In December 2010, a non-randomized, open-label, phase II study (&lt;ulink linkID="73372" linkType="Protocol"&gt;NCT01266070&lt;/ulink&gt;; 2010-0650) was planned in patients with Von Hippel-Lindau syndrome (expected n = 25) in the US, to assess the safety and efficacy of dovitinib. The study began in November 2012 and at that time was expected to be completed in November 2015 [&lt;ulink linkID="1178215" linkType="Reference"&gt;1178215&lt;/ulink&gt;]. In January 2016,  clinical data were presented at the ASCO Genitourinary Cancers Symposium in San Francisco, CA. The adverse events reported were rash, diarrhea, fatigue, pruritus, LFT abnml, cytopenia, pancreatic enzyme abnormal, mucositis and dyspenia. Patients discontinued treatment due to non-compliant, adverse events or disease progression and study completed [&lt;ulink linkID="1727534" linkType="Reference"&gt;1727534&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2010, a non-randomized, open-label, phase II trial (&lt;ulink linkID="63785" linkType="Protocol"&gt;NCT01058434&lt;/ulink&gt;; CTKI258A2204; EUDRACT 2009-012417-22) was initiated in the US, Canada, Germany and Turkey in patients (expected n = 80) with relapsed or refractory multiple myeloma with or without t(4;14) translocation. At that time, trial completion was expected in July 2012  [&lt;ulink linkID="1178898" linkType="Reference"&gt;1178898&lt;/ulink&gt;]. In December 2012, data from the multicenter, two-stage study were presented at the 54th ASH Annual meeting in Atlanta, GA. Patients (n = 43) received dovitinib (500 mg/day). Of 26 patients who were t(4;14)-negative, 9 and 13 patients had stable disease (SD) and progressive disease (PD), respectively; among 13 patients who were t(4;14)-positive, SD and PD were observed in 8 and 3 patients as best responses, respectively. Of six patients treated with dovitinib plus dexamethasone regimen, one patient  continued the treatment. In either group, objective responses were not observed. The study was not proceeded to stage 2 due to lack of efficacy [&lt;ulink linkID="1347743" linkType="Reference"&gt;1347743&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2005, Chiron began US and UK phase I trials in multiple myeloma (CHIR-258-003 and CHIR-258-004) [&lt;ulink linkID="605481" linkType="Reference"&gt;605481&lt;/ulink&gt;], [&lt;ulink linkID="636997" linkType="Reference"&gt;636997&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;An open-label dose-escalation phase I study was initiated in September 2004 in the US to evaluate dovitinib in AML (&lt;ulink linkID="27615" linkType="Protocol"&gt;NCT00279773&lt;/ulink&gt;).  The primary outcomes were MTD and DLTs. The trial was to enroll 34 patients, however it was terminated due to time-dependent drug accumulation [&lt;ulink linkID="1353100" linkType="Reference"&gt;1353100&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2004, Chiron had initiated a UK phase I study (CHIR-258-002) in AML [&lt;ulink linkID="565808" linkType="Reference"&gt;565808&lt;/ulink&gt;]. In December 2005, data were presented at the 47th ASH meeting in Atlanta, GA. In CHIR-258-002, AML patients received single oral doses of dovitinib, ranging between 50 to 400 mg for 7 days, followed by a 7-day rest period. The drug was well tolerated; adverse events were generally mild to moderate, but there was one incidence of grade 4 fatigue. All patients exhibited reductions or stabilization of peripheral blasts, and reduction or stabilization in bone marrow blasts was seen in all but one of the nine evaluable patients. At that time accrual was continuing at the 400 mg dose level [&lt;ulink linkID="640032" linkType="Reference"&gt;640032&lt;/ulink&gt;], [&lt;ulink linkID="640034" linkType="Reference"&gt;640034&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;In April 2010, a phase II study (&lt;ulink linkID="57269" linkType="Protocol"&gt;NCT00831792&lt;/ulink&gt;; 2008-0510) in castrate-resistant prostate cancer patients (n = 40) began. Patients would receive 500 mg a day for 5 days followed by 2 days of rest for 4-week cycles. The primary endpoint was patient overall survival time and early response time as characterized by a drop in PSA. The study was due to be completed in April 2012 [&lt;ulink linkID="1129284" linkType="Reference"&gt;1129284&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Breast cancer&lt;/subtitle&gt;In April 2012, a multicenter, randomized, double-blind, placebo-controlled, phase II trial (&lt;ulink linkID="84686" linkType="Protocol"&gt;NCT01528345&lt;/ulink&gt;; CTKI258A2210; 2011-001230-42) was initiated in the US, China, Egypt, Europe, South Africa, South America and Taiwan to evaluate the safety and efficacy of dovitinib combined with fulvestrant in postmenopausal patients (expected n = 150, Taiwan n = 10) with HER2- and HR+ breast cancer that had evidence of disease progression on or after prior endocrine therapy [&lt;ulink linkID="1632536" linkType="Reference"&gt;1632536&lt;/ulink&gt;], [&lt;ulink linkID="1632537" linkType="Reference"&gt;1632537&lt;/ulink&gt;]. In November 2014, recruitment was ongoing. At that time, trial completion was expected in October 2015 [&lt;ulink linkID="1632536" linkType="Reference"&gt;1632536&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2012, an open-label, single-group, safety/efficacy phase II study (&lt;ulink linkID="73167" linkType="Protocol"&gt;NCT01262027&lt;/ulink&gt;; 2010-0296) was initiated in the US in patients (n = 33) with inflammatory breast cancer. The trial was expected to complete in January 2016  [&lt;ulink linkID="1441754" linkType="Reference"&gt;1441754&lt;/ulink&gt;]. In December 2014, clinical data were presented from 22 patients at the 37th Annual San Antonio Breast Cancer Symposium in San Antonio, TX. Dovitinib was found to be well tolerated without any clinical activity and one patient had stable disease. The study was found to be closed at the first stage of Simon's design due to futility. The most commonly reported adverse event was fatigue which occurred during the first 4 weeks of treatment  [&lt;ulink linkID="1616497" linkType="Reference"&gt;1616497&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2009, a phase II study (&lt;ulink linkID="59602" linkType="Protocol"&gt;NCT00958971&lt;/ulink&gt;; CTKI258A2202, 2008-006430-10) began in Canada and Europe in patients (n = 200) with FGFR1-amplified and non-amplified metastatic or advanced HER2 negative breast cancer. The primary endpoint was complete or partial response, and the study was due to be completed in September 2011. In September 2010, the trial was started in Taiwan [&lt;ulink linkID="1129303" linkType="Reference"&gt;1129303&lt;/ulink&gt;]. In June 2011, data were presented at the 47th ASCO meeting in Chicago, IL. The trial did not meet the protocol-defined efficacy to continue into later phase  trials, however, dovitinib exhibited antitumor activity in the subgroup of patients with FGFR+, HR+ gene types, as demonstrated by a biomarker sub-study of the trial [&lt;ulink linkID="1194090" linkType="Reference"&gt;1194090&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Urothelial cancer&lt;/subtitle&gt;In June 2016, clinical data were presented from a phase II (&lt;ulink linkID="99302" linkType="Protocol"&gt;NCT01732107&lt;/ulink&gt;) trial in 13 patients at the 52nd ASCO meeting in Chicago, IL. Patients (n = 13) received dovitinib 500 mg, po qd (5 days on / 2 days off) on q28d cycles. Clinical response (primary endpoint), progressive disease was 17.5 and 2.7 months, respectively. Dovitinib was not feasible due to frequent treatment related toxicity upon long term administration. Grade 3 or 4 adverse events (AEs) and other AEs occurred in &amp;gt;20% of patients [&lt;ulink linkID="1769577" linkType="Reference"&gt;1769577&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2010, a phase II study (&lt;ulink linkID="35717" linkType="Protocol"&gt;NCT00790426&lt;/ulink&gt;; I258A2201; 2008-005870-11) began in patients (n = 80) with FGFR3-mutated and FGFR3 wild type advanced urothelial carcinoma in the US, Canada, Europe and Taiwan. The primary endpoint was overall response rate and the study was due to be completed in March 2012 [&lt;ulink linkID="1129310" linkType="Reference"&gt;1129310&lt;/ulink&gt;]. In February 2013, data were presented at the Genitourinary Cancers Symposium in Orlando, FL. Dovitinib demonstrated limited single-agent activity. Due to insufficient response in the FGFR3 wild type group of patients and less than 6 months worth of treatment in the FGFR3-mutant group the study was terminated [&lt;ulink linkID="1384344" linkType="Reference"&gt;1384344&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hepatocellular carcinoma&lt;/subtitle&gt;In August  2011, a randomized, open-label, phase II study (&lt;ulink linkID="71868" linkType="Protocol"&gt;NCT01232296&lt;/ulink&gt;; CTKI258A2208) was initiated in patients with advanced hepatocellular carcinoma ( n  = 230) to assess the safety and efficacy of dovitinib. In January 2013, the study was expected to complete in July 2013 [&lt;ulink linkID="1178464" linkType="Reference"&gt;1178464&lt;/ulink&gt;]. In January 2015, clinical data were presented at the 2015 ASCO Gastrointestinal Cancer Symposium in San Francisco, CA.  Most common adverse events included diarrhea (62.0%), decreased appetite (43.0%), nausea and vomiting (40.5%), fatigue (35.4%), rash (34.2%) and pyrexia (30.4%) in dovitinib arm and palmar-plantar erythrodysesthesiasyndrome (66.3%), diarrhea (42.2%) and decreased appetite (31.3%) in sorafenib arm [&lt;ulink linkID="1632709" linkType="Reference"&gt;1632709&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2012, an IND application for hepatocellular carcinoma was filed with the SFDA; in January 2013, approval to conduct a clinical trial was obtained in China [&lt;ulink linkID="1384043" linkType="Reference"&gt;1384043&lt;/ulink&gt;], [&lt;ulink linkID="1385085" linkType="Reference"&gt;1385085&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Endometrial cancer&lt;/subtitle&gt;In December 2011, a non-randomized, open-label, phase II study (&lt;ulink linkID="78558" linkType="Protocol"&gt;NCT01379534&lt;/ulink&gt;; CTKI258A2211) was initiated in patients with advanced and/or metastatic endometrial cancer (expected n = 80) in the US, Europe, Brazil, South Korea and New Zealand, to assess the safety and efficacy of dovitinib. At that time, the study was expected to  complete in September 2014 [&lt;ulink linkID="1230990" linkType="Reference"&gt;1230990&lt;/ulink&gt;].  In September 2014,  data were presented at the 39th European Society for Medical Oncology congress in Madrid, Spain. In the mutated and non-mutated groups, the respective 18-week progression-free survival rate was 32 and 29%, 1 and 5 patients achieved partial response, respectively and 13 and 11 patients had stable disease, respectively  [&lt;ulink linkID="1596297" linkType="Reference"&gt;1596297&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Gastrointestinal stromal tumors&lt;/subtitle&gt;In November 2011, an open-label, phase II study (&lt;ulink linkID="82646" linkType="Protocol"&gt;NCT01478373&lt;/ulink&gt;; CTKI258AIC02; 2011-001725-24; DOVIGIST) was planned in patients with GIST refractory and/or intolerant to &lt;ulink linkID="11460" linkType="Drug"&gt;imatinib&lt;/ulink&gt; (expected n = 36) in Europe, to assess the safety and efficacy of dovitinib. At that time, the study was scheduled to begin in January 2012 and complete in December 2013 [&lt;ulink linkID="1243285" linkType="Reference"&gt;1243285&lt;/ulink&gt;]. In May 2012, the trial began [&lt;ulink linkID="1243285" linkType="Reference"&gt;1243285&lt;/ulink&gt;]. In October 2012, clinical data were presented at the 37th European Society for Medical Oncology Congress in Vienna, Austria. Patients (n = 30) received dovitinib (500 mg po qd) on a 5 days on or 2 days off schedule.  At week 24, stable disease and progressive disease was observed in 3 and 22 patients, respectively. At a median follow-up of 6.4 months, the median overall survival and median progression-free survival (PFS) were 6.7 and 3.6 months, respectively, in surviving patients. At 6 months, the rate of PFS was 10.6% [&lt;ulink linkID="1325903" linkType="Reference"&gt;1325903&lt;/ulink&gt;]. In September 2014, further data were presented at the 39th European Society for Medical Oncology congress in Madrid, Spain. At 12 weeks, disease control rate was 52.6% (primary end point). The median progression-free survival duration was observed to be 141 days. Partial response was achieved by two patients; stable disease and progressive disease was seen in 16 and 5 patients at end of the study [&lt;ulink linkID="1596189" linkType="Reference"&gt;1596189&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Adenoid carcinoma&lt;/subtitle&gt;In October 2016, data from an Ontario Clinical Oncology Group DOVE study (&lt;ulink linkID="90771" linkType="Protocol"&gt;NCT01678105&lt;/ulink&gt;), which evaluated the efficacy of dovitinib, in patients with advanced adenoid cystic carcinoma of the salivary glands, were presented at the ESMO 2016 Congress in Copenhagen, Denmark. Patients (n = 21) received dovitinib (500 mg, po) for 5 days on/2 days off on a 28-day cycle with response assessed every 12 weeks. Clinical benefit rate (primary outcome) was 7 of 21 patients. Month-12 progression free survival (PFS) and one-year overall survival (OS) was 37.6 and 61.6%, respectively [&lt;ulink linkID="1805840" linkType="Reference"&gt;1805840&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2012, an open-label, phase II study (&lt;ulink linkID="84611" linkType="Protocol"&gt;NCT01524692&lt;/ulink&gt;; IRB-HSR# 15627) was planned in patients with adenoid cystic carcinoma (expected n = 10) in the US, to assess the safety and efficacy of dovitinib. At that time, the study was scheduled to complete in January 2014 [&lt;ulink linkID="1261087" linkType="Reference"&gt;1261087&lt;/ulink&gt;]. In June 2013,  data from 21 patients were presented at the 49th ASCO meeting in Chicago, IL. Patients received dovitinib (500 mg) for 5 days on, 2 days off. Patients were permitted with two dose reductions. The time to progression in patients with partial response (n = 2), stable disease (n = 16), progressive disease (n =  1) and stable disease for &amp;gt; 6 months  (n = 6) were 10, 7.5, 2.0 and 11.4 months, respectively. The median time of progression free survival was 8 months [&lt;ulink linkID="1430057" linkType="Reference"&gt;1430057&lt;/ulink&gt;]. In May 2015, further clinical data were presented at the 51st ASCO meeting in Chicago, IL. The overall response rate was 6% and partial response or stable disease of &amp;gt;/= 4 months was observed in 71% of patients [&lt;ulink linkID="1662018" linkType="Reference"&gt;1662018&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Melanoma&lt;/subtitle&gt;In April 2006, a non-randomized, open-label, phase I/II study (&lt;ulink linkID="25639" linkType="Protocol"&gt;NCT00303251&lt;/ulink&gt;; CTKI258A2105) was initiated in patients with advanced or metastatic melanoma (n = 47) in the US, to assess the safety and efficacy of dovitinib. In September 2009, the study was completed [&lt;ulink linkID="1263821" linkType="Reference"&gt;1263821&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Mesothelioma&lt;/subtitle&gt;In January 2013, an open label, single group assignment, interventional, treatment, safety/efficacy, phase II trial (&lt;ulink linkID="104836" linkType="Protocol"&gt;NCT01769547&lt;/ulink&gt;; OCOG-2012-DOVE-M) was expected to begin in Canada in March 2013, in patients (expected n = 26) with advanced malignant pleural mesothelioma (MPM) which has progressed following prior platinum-antifolate chemotherapy. At that time, the trial was estimated to complete in June 2016; in July 2013, the trial was initiated [&lt;ulink linkID="1439473" linkType="Reference"&gt;1439473&lt;/ulink&gt;]. In September 2015, clinical data were presented from 12 patients at the IASLC 16th World Conference on Lung Cancer in Denver, CO.   Unconfirmed partial response, stable disease and progressive disease were noted in one, five and two patients, respectively. The median progression-free survival and overall survival were 2.6 and 4 months, respectively. Overall, dovitinib showed minimal activity in MPM [&lt;ulink linkID="1693589" linkType="Reference"&gt;1693589&lt;/ulink&gt;]. In May 2015, the trial was terminated [&lt;ulink linkID="1439473" linkType="Reference"&gt;1439473&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Adrenocortical carcinoma&lt;/subtitle&gt;In June 2013, data were presented from a phase II, open-label study (&lt;ulink linkID="84184" linkType="Protocol"&gt;&lt;/ulink&gt;&lt;ulink linkID="84184" linkType="Protocol"&gt;NCT01514526&lt;/ulink&gt;) in  17 patients  with metastatic nonresectable adrenocortical carcinoma at the 49th ASCO meeting in Chicago, IL. Overall, 35% of patients had stable disease lasting more than 4 months and 65% of patients had progressive disease. The median PFS duration was 1.8 months [&lt;ulink linkID="1426082" linkType="Reference"&gt;1426082&lt;/ulink&gt;]. In June 2014, similar data were presented from this study (SOGUG 2011-03) at the 50th ASCO meeting in Chicago, IL [&lt;ulink linkID="1562828" linkType="Reference"&gt;1562828&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Glioblastoma&lt;/subtitle&gt;In December 2012, an open-label, interventional, single-group assigned, phase II study (&lt;ulink linkID="102378" linkType="Protocol"&gt;NCT01753713&lt;/ulink&gt;; CASE4312, NCI-2012-02284) to assess the efficacy of dovitinib in the US in patients (expected n = 14) with recurrent of progressive glioblastoma was initiated. At that time, the trial was expected to be completed in December 2013 [&lt;ulink linkID="1448594" linkType="Reference"&gt;1448594&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Liver cancer&lt;/subtitle&gt;In July 2018, a randomized phase III   pivotal trial for liver cancer was underway [&lt;ulink linkID="2057182" linkType="Reference"&gt;2057182&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In November 2015, data were presented from study (&lt;ulink linkID="121120" linkType="Protocol"&gt;NCT01831726&lt;/ulink&gt;), a part of signature program at the 27th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA.). The activity of dovitinib (TK-1258), a tyrosine kinase inhibitor, for the potential treatment of head and neck cancers, including adenoid cystic carcinoma (ACC), head and neck squamous cell carcinoma (HNSCC), and salivary gland cancer, was evaluated, in patients (n = 80).The patients in HNSCC cohort reported distinct mutational profile compared to ACC cohort and lower mutational load, was observed in ACC cohort [&lt;ulink linkID="1711316" linkType="Reference"&gt;1711316&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, an open-label, single-group assignment, pharmacodynamics, phase II trial (&lt;ulink linkID="143476" linkType="Protocol"&gt;NCT01888965&lt;/ulink&gt;; CTK1258AUS16T; Pro063) was planned to be initiated in patients (expected n = 60) with colorectal and pancreas cancer in the US. At that time, the trial was planned to be initiated in August 2013 and complete in August 2016 [&lt;ulink linkID="1456992" linkType="Reference"&gt;1456992&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2013, an open-label, single group assignment phase II trial (&lt;ulink linkID="90646" linkType="Protocol"&gt;NCT01676714&lt;/ulink&gt;; UCDCC#231, CTKI258AUS21T) was initiated in patients (estimated n = 35) with advanced NSCLC and advanced colorectal cancer in the US. The trial was expected to complete in October 2016 [&lt;ulink linkID="1440754" linkType="Reference"&gt;1440754&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, an open-label, safety/efficacy phase II trial (&lt;ulink linkID="96666" linkType="Protocol"&gt;NCT01719549&lt;/ulink&gt;; AMC1202) was initiated in Korea in patients (n = 31) with  metastatic or unresectable gastric cancer.  The trial was expected to complete in March 2014 [&lt;ulink linkID="1442057" linkType="Reference"&gt;1442057&lt;/ulink&gt;]. In March 2016, it was reported at the ESMO Symposium on Signaling Pathways in Cancer 2016 that the trial was using dovitinib as a subtype-specific therapy for FGFR2-amplified gastric cancers [&lt;ulink linkID="1741790" linkType="Reference"&gt;1741790&lt;/ulink&gt;]. The trial was still recruiting patients [&lt;ulink linkID="1741940" linkType="Reference"&gt;1741940&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012,   a prospective, multicentered, single-armed phase II study (&lt;ulink linkID="86461" linkType="Protocol"&gt;NCT01576380&lt;/ulink&gt;; CTKI258A1201)   in  patients (n = 11) with advanced scirrhous gastric carcinoma, who have progressed after one or two prior systemic treatments was initiated to evaluate efficacy and safety of dovitinib. In September 2013, the study was completed [&lt;ulink linkID="1905409" linkType="Reference"&gt;1905409&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I studies&lt;/subtitle&gt;In June 2014, data were presented from a multicenter, open-label, phase I study in 39 patients with advanced solid tumorsat the 50th ASCO meeting in Chicago, IL. Overall, dovitinib was a strong inducer of CYP1A2 and moderate inducer of CYP2C19 and also had limited impact on CYP2C9 [&lt;ulink linkID="1562091" linkType="Reference"&gt;1562091&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;InJune 2014, data were presented from an ongoing phase I, two-part study in  18 advanced solid tumor patients at the 50th ASCO meeting in Chicago, IL.  The 300 mg dovitinib daily x 5 then 2 days off continuously + gemcitabine and capecitabine was established as the MTD. Median survival was not reached in first- and second-line advanced pancreatic cancer patients [&lt;ulink linkID="1562805" linkType="Reference"&gt;1562805&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, data were presented from an ongoing open-label, multicenter, randomized, two-way crossover phase I study  in 173 patients with advanced solid tumors at the 105th AACR meeting in San Diego, CA. Partial response was achieved by one patient. Stable and progressive diseases were seen in 55 and 48 patients, respectively. The AUC(infinity) and Cmax values of dovitinib were found to be similar between the tablet and capsule formulations [&lt;ulink linkID="1539581" linkType="Reference"&gt;1539581&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2013, a  phase I-II trial (&lt;ulink linkID="150202" linkType="Protocol"&gt;NCT01921673&lt;/ulink&gt;) of dovitinib plus docetaxel as second-line chemotherapy was initiated in patients with metastatic or unresectable gastric cancer after first-line Chemotherapy failure. The trial was completed in November 2015 [&lt;ulink linkID="1741932" linkType="Reference"&gt;1741932&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, data were presented from a randomized, crossover, phase I study (&lt;ulink linkID="67902" linkType="Protocol"&gt;NCT01155713&lt;/ulink&gt;) in advanced solid tumor patients at the 49th ASCO meeting in Chicago, IL. The FMI and CSF formulations showed comparable oral bioavailability. Overall, 30 patients had stable disease and 11 patients had stable disease for &amp;gt; 120 days [&lt;ulink linkID="1425833" linkType="Reference"&gt;1425833&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2012, a single group, open-label, phase I trial (&lt;ulink linkID="84238" linkType="Protocol"&gt;NCT01515969&lt;/ulink&gt;; LUN0044, NCI-2011-03333, SU-08012011-8166, 21659) was initiated in the US in patients (expected n=30) with advanced NSCLC to determine the toxicity of erlotinib and dovitinib. The trial was expected to complete in December 2013. In February 2013, patient enrollment was suspended. At that time, the company expected interim analysis of pharmacokinetics and toxicity data [&lt;ulink linkID="1437240" linkType="Reference"&gt;1437240&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2012, non-randomized, open-label, single group assessment, safety, efficacy investigator-led phase I trial (&lt;ulink linkID="85487" linkType="Protocol"&gt;NCT01548924&lt;/ulink&gt;; CNIO-BR-01-2011) of dovitinib plus paclitaxel was initiated in patients (expected n = 24) with solid tumors. At that time, the study was expected to be completed in August 2013. In July 2014, the trial was terminated [&lt;ulink linkID="1592773" linkType="Reference"&gt;1592773&lt;/ulink&gt;], [&lt;ulink linkID="1593054" linkType="Reference"&gt;1593054&lt;/ulink&gt;]; later the month data were published. Data demonstrated that patients with a specific variant in the RET gene were found to be more sensitive to dovitinib [&lt;ulink linkID="1593071" linkType="Reference"&gt;1593071&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2009, Japanese phase I trials were expected to begin in 2009 [&lt;ulink linkID="992023" linkType="Reference"&gt;992023&lt;/ulink&gt;]. 	In November 2011, an open-label, phase I study (&lt;ulink linkID="82422" linkType="Protocol"&gt;NCT01471548&lt;/ulink&gt;; CTKI258A1101) was initiated in patients with advanced solid tumors (expected n = 28) in Japan, to assess the study and efficacy of dovitinib [&lt;ulink linkID="1241286" linkType="Reference"&gt;1241286&lt;/ulink&gt;]. In June 2012, clinical data were presented at the 48th ASCO meeting in Chicago, IL. Of 28 patients, one partial response was seen, in a patient with peritoneal cancer treated with 400 mg of the drug. A further 9 patients achieved stable disease. The  maximum tolerated dose was defined as   500 mg  [&lt;ulink linkID="1299658" linkType="Reference"&gt;1299658&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2008, data were presented at the 44th annual ASCO meeting in Chicago, IL. In a phase I dose finding and biomarker study, at the MTD of 400 mg, three of six patients evaluated had objective vascular responses [&lt;ulink linkID="912084" linkType="Reference"&gt;912084&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2006, phase I data were presented at the 42nd ASCO meeting in Atlanta, GA. A total of 35 patients were treated in four intermittent dosing cohorts (25, 50, 75 and 100 mg/day) and three continuous dosing cohorts (100, 125 and 175 mg/day) all qd. Treatment was 7 days on, 7 days off with a subsequent protocol amendment to daily dosing. The plasma pharmacokinetic (PK) values were linear between 25 and 175 mg doses with respect to Cmax and AUC. DLTs occurred at 175 mg; the MTD was 125 mg. Treatment was associated with stable disease [&lt;ulink linkID="670417" linkType="Reference"&gt;670417&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 4Q03, a UK CTX was approved. The phase I CHIR-258-001study was to enroll three cohorts of three solid tumor patients. Chiron expected to complete enrollment during 2004 [&lt;ulink linkID="519079" linkType="reference"&gt;519079&lt;/ulink&gt;]. By June 2004, the first two cohorts had been treated with 25 and 50 mg/day dovitinib on a week-on, week-off regimen. No clinically significant toxicities were observed. A reduction in phosphorylated ERK was observed in patient peripheral blood lymphocytes 4 to 24 h following the first dose. Pharmacodynamic studies showed dose-dependent plasma concentration and supported once-daily dosing [&lt;ulink linkID="547198" linkType="reference"&gt;547198&lt;/ulink&gt;]. By September 2004, the third cohort had completed treatment with 75 mg/day dovitinib and a 100 mg/day dose level had been initiated. No clinically significant toxicities had been detected at this point [&lt;ulink linkID="561951" linkType="Reference"&gt;561951&lt;/ulink&gt;]. In May 2005, clinical data on dovitinib were presented at the 41st ASCO meeting in Orlando, FL. In the dose-escalation multicenter phase I trial, the safety, PK and pharmacodynamic (PD) parameters were assessed in patients with advanced solid tumors. The dosing regimens included either single daily doses of dovitinib (25 to 100 mg) in repeated 7 day on/ 7 day off cycles, or a &amp;gt;= 100 mg daily dose of dovitinib for one 7 day on/ 7 day off cycle, followed by continuous daily dosing thereafter. Preliminary results showed evidence of antitumor activity in dovitinib-treated patients; 7 of 32 patients (32%) had achieved stable disease at their first evaluation. Four patients reported stable disease for &amp;gt;= 4 months. PK and PD data revealed plasma exposure increased proportionally with dose and that plasma exposure in the 100 mg dose was in the range at which preclinical efficacy was observed. Dovitinib dose-dependently modulated ERK phosphorylation in unstimulated peripheral blood leukocytes from healthy subjects [&lt;ulink linkID="601346" linkType="Reference"&gt;601346&lt;/ulink&gt;], [&lt;ulink linkID="603319" linkType="Reference"&gt;603319&lt;/ulink&gt;]. In November 2005, further data from this study were presented at the 17th AACR-NCI-EORTC conference in Philadelphia, PA. dovitinib inhibited ERK and STAT5 phosphorylation in peripheral AML blasts from treated patients [&lt;ulink linkID="636997" linkType="Reference"&gt;636997&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2015, preclinical data were presented at the 106th AACR meeting in Philadelphia, PA.  In UZLX-GIST2 patient-derived xenograft model, dovitinib (30 mg/kg, po, qd) treatment showed 73% reduction of tumor growth when compared with imatinib 100 mg/kg po treatment (9%). In UZLX-GIST9 PDX model, dovitinib treatment was stabilized the tumor growth when compared with imatinib treatment. In both the models, dovitinib treatment was reduced the microvessel density when compared with control [&lt;ulink linkID="1648413" linkType="Reference"&gt;1648413&lt;/ulink&gt;]. In May 2015, similar data were presented at the 51st ASCO meeting in Chicago, IL [&lt;ulink linkID="1663638" linkType="Reference"&gt;1663638&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, preclinical data were presented at the 104th AACR Annual Meeting in Washington, DC.   For 14- and 21-day treatment cycles, imatinib and dovitinib were found to be well tolerated, in vivo. In a nu/nu mouse xenograft model bearing GIST-T1 xenografts, imatinib (100 mg/kg by po bid) and dovitinib (60 mg/kg daily) showed tumor regression (TR) of 52 and 59%, respectively, and the median time to regrowth (MTR) was 69 days for both imatinib and dovitinib when compared with the vehicle (31 days) during the 14-day cycle. Imatinib (100 mg/kg by po bid) and dovitinib (30 mg/kg daily) showed TR  of 66 and 36%, respectively, and the respective MTR was 81 and 69 days when compared with the vehicle (27 days) during the 21-day treatment cycle. At that time, studies were ongoing [&lt;ulink linkID="1400280" linkType="Reference"&gt;1400280&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, data from HCC models were presented at the 103rd AACR meeting in Chicago, IL. In SK-HEP1 cells, dovitinib induced G2/M cell cycle arrest, inhibited colony formation in soft agar and blocked the bFGF-induced cell migration. Basal expression and FGF-induced phosphorylation of FGFR-1, FRS2-alpha and ERK1/2 were found to be inhibited by dovitinib. In vivo, the growth of six of the HCC cell lines tested was found to be potently inhibited by dovitinib. Dovitinib-treatment also resulted in dephosphorylation of retinoblastoma, upregulation of p-histone H2A-X and p27, and downregulation of p-cdk-2 and cyclin B1, resulting in decreased cellular proliferation and tumor cell apoptosis induction.   In an orthotopic mouse model, dovitinib-treatment resulted in potent inhibition of primary tumor growth and lung metastasis and significant prolongation of the survival [&lt;ulink linkID="1276337" linkType="Reference"&gt;1276337&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, data were presented at the 23rd AACR-NCI-EORTC International Conference in San Francisco, CA. In immune-deficient mice implanted with adenoid cystic carcinoma,  dovitinib was found to inhibit the phosphorylation of FGFR-1 in the primary tumor tissues in a time-dependent manner. In four of five tested patient-derived salivary gland tumor models, treatment with dovitinib alone resulted in a statistically significant tumor growth inhibition (&amp;gt; 85%); in sensitive models, the combination of dovitinib and &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; demonstrated an additive effect in  tumor growth inhibiting, including partial and complete tumor responses in some models [&lt;ulink linkID="1240063" linkType="Reference"&gt;1240063&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011,  data were presented at the 102nd AACR meeting in Orlando, FL. In vitro, dovitinib inhibited the growth of patient-derived cancer cell lines exhibiting FGFR3 overexpression.  In a mouse homograft model with active FGFR3, dovitinib at 10, 30 and 50 mg/kg showed tumor inhibition of 35, 85 and 96%, respectively. In the NIH3T3/FGF3 s249C subcutaneous mouse model, dovitinib inhibited tumor growth in a dose-dependent manner and this inhibition correlated with inhibition of FGFR3 autophosphorylation. Dovitinib (60 mg/kg) showed most potent tumor regression at maximal tolerated doses when compared with high doses of &lt;ulink linkID="12973" linkType="Drug"&gt;sunitinib&lt;/ulink&gt; or &lt;ulink linkID="29831" linkType="Drug"&gt;sorafenib&lt;/ulink&gt;. Dovitinib inhibited RT-112 growth urothelial carcinoma tumor xenografts at 15, 30 and 60 mg/kg. Dovitinib was found to be well tolerated [&lt;ulink linkID="1175230" linkType="Reference"&gt;1175230&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, preclinical data were presented at the 102nd AACR meeting in Orlando, FL, demonstrating the drug to have concentration-dependent antiproliferative activity against all 20 endometrial cancer cell lines tested with IC50's ranging from 0.42 to 3.06 microM, with high activity in cell lines carrying an FGFR2 mutation. In xenograft models of MFE296, HEC-1A and SNG-M cancer cells, dose-dependent antitumor activity was also seen [&lt;ulink linkID="1175241" linkType="Reference"&gt;1175241&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2009, preclinical data were presented at the 100th AACR meeting in Denver, CO, showing that dovitinib&lt;i&gt; &lt;/i&gt;significantly reduced tumor growth, final tumor weights and lymph node and liver metastases in mouse xenografts models of pancreatic cancer [&lt;ulink linkID="997856" linkType="Reference"&gt;997856&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, preclinical data were presented at the 99th AACR meeting in San Diego, CA. Dovitinib inhibited the growth of NIH3T3/FGF-R3S249C tumor homografts and RT112/luc orthotopic bladder tumors  implanted sc in nude mice [&lt;ulink linkID="894626" linkType="Reference"&gt;894626&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007, preclinical data were presented at the 98th AACR meeting in Los Angeles, CA. In in vitro clonogenic assays, dovitinib activity was observed in all melanoma cells regardless of FGFR1-4 expression levels, or wt/mutant Ras/B-Raf status. In vivo efficacy was evaluated in two different subcutaneous melanoma xenograft models: CHL-1 (WT K-Ras and WT B-Raf) and A375M (mutant B-Raf) in athymic nude mice. Daily oral dosing of the compound (at concentrations known to inhibit FGFR signaling in vivo) resulted in significant tumor growth inhibition of both tumor xenograft models. The combination of dovitinib with &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; plus &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; resulted in enhanced activity against both CHL-1 and A375M tumors and was well tolerated compared to monotherapy. In the CHL-1 model, treatment with carboplatin plus paclitaxel at MTDs showed no tumor growth inhibition (TGI), whereas dovitinib therapy resulted in TGI of 44%. The combination of all three agents gave a TGI of 70%. In the A375 model, animals dosed with the carboplatin + paclitaxel combination resulted in 35% TGI, while for dovitinib treatment alone resulted in a 58% TGI and the combination of all three agents resulted in 73% TGI [&lt;ulink linkID="783234" linkType="Reference"&gt;783234&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, preclinical data were presented at the 48th ASH meeting in Orlando, FL. Dovitinib was found to selectively inhibit proliferation and survival of  ZNF-198-F-GFR1-transformed Ba/F3 cells, phosphorylation of the FGFR1 fusion protein and downstream signalling molecules including ERK and STAT5. The drug was also active against primary cells from myeloproliferative syndrome patients in colony growth and liquid culture assays [&lt;ulink linkID="750340" linkType="Reference"&gt;750340&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2006, at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague, Czech Republic, preclinical data were presented showing that multiple dovitinib targets were expressed by prostate tumor xenografts and cell lines, and that the agent inhibited growth of prostate tumor cell lines in soft agar; it was also potent against DU145, 22RV1 and PC3 xenograft tumors in male nude mice, and the addition of &lt;ulink linkID="2953" linkType="Drug"&gt;taxotere&lt;/ulink&gt; to dovitinib added to its antitumor effects in vivo [&lt;ulink linkID="742719" linkType="Reference"&gt;742719&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2005, preclinical data were presented at the 47th ASH meeting in Atlanta, GA.  Mice were injected via the tail vein with human KMS-11-luc cells, and MM lesions developed in almost all mice, mainly localized in spine, skull and pelvis. Further work showed that daily oral administration of dovitinib to this model at 20 mg/kg, a dose that was demonstrated to inhibit phosphorylation of ERK in KMS-11-luc tumors in vivo, resulted in a significant inhibition of tumor growth, and that this antitumor activity led to significant improvement in animal survival compared to vehicle treatment in this model. In vitro combination studies with dexamethasone and bortezomib in KMS-11 cells demonstrated synergistic and additive effects, respectively [&lt;ulink linkID="641690" linkType="Reference"&gt;641690&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, preclinical data were presented at the 96th AACR meeting in Anaheim, CA. Dovitinib exhibited multi-target kinase selectivity against Class III, IV and V receptor tyrosine kinases in vitro. The anti-tumor efficacy of dovitinib was evaluated in a variety of murine and human solid tumor models (colon, prostate, breast, ovarian) and hematological cancers (leukemia and myeloma), in comparison with other more selective kinase inhibitors currently in clinical development. In solid tumor models, dovitinib exhibited potent tumor inhibition, including regression, with greater efficacy than selective RTK inhibitors, a comparable potency to an RTK inhibitor with a similar target profile and 'broad' selectivity. However, dovitinib achieved more potent antitumor activity using cyclic or intermittent dosing schedules. Pharmacodynamic studies showed that target inhibition and suppression of signaling pathways were maintained for 24 h, followed by induction of tumor cell apoptosis [&lt;ulink linkID="593443" linkType="Reference"&gt;593443&lt;/ulink&gt;]. To develop a pharmacokinetic-pharmacodynamic model of  tumor growth inhibition following repeated oral doses of dovitinib, murine xenograft models of subcutaneously-grown KM12L4a (colon tumor) or MV4;11 (representing FLT-3 ITD AML) cells were evaluated. KM12L4a mice received 3 to 300 mg/kg/day dovitinib, and mice with MV4;11 tumors were treated with 1 to 30 mg/kg/day dovitinib, for up to 3 weeks. The plasma pharmacokinetics of dovitinib fitted a one-compartment linear model, and tumor growth kinetics in drug- and vehicle-treated groups were described by an indirect effect model. An 'effect' compartment accounted for the lag between plasma concentrations of dovitinib and tumor growth. Dovitinib concentrations of approximately 5 to 50 ng/ml were predicted to result in significant antitumor activity [&lt;ulink linkID="597290" linkType="Reference"&gt;597290&lt;/ulink&gt;]. A third study was presented at the same meeting.  This comparative study was carried out by &lt;ulink linkID="13601" linkType="Company"&gt;Abbott Laboratories&lt;/ulink&gt; to analyze the inhibition of CSF-1R signaling in enzymatic and cellular assays, and comparing its inhibitor, &lt;ulink linkID="53059" linkType="Drug"&gt;ABT-869&lt;/ulink&gt;, with dovitinib [&lt;ulink linkID="596245" linkType="Reference"&gt;596245&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2004, preclinical data were presented at the 46th ASH meeting in San Diego, CA. In MM cells with the t(4;14) translocation, dovitinib demonstrated an IC50 value of 90 to 550 nM in cytotoxicity assays. Dovitinib has a much higher IC50 value in MM cells lacking the t(4;14) translocation. Dovitinib also induced apoptosis in primary t(4;14) MM samples with an IC50 value of  500 nM and retained activity in cells that overexpress wild-type FGFR3 or a variety of FGFR3 mutants [&lt;ulink linkID="576672" linkType="Reference"&gt;576672&lt;/ulink&gt;], [&lt;ulink linkID="573953" linkType="Reference"&gt;573953&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2004, dovitinib had shown potent activity against several growth factor-related kinases, with IC50 values of 27, 2, 0.1, ~10 and 8 nM obtained against PDGFR b, c-Kit, Flt-3, VEGFR1/2/3 and FGFR1/3 respectively. It showed minimal activity against 25 other kinases [&lt;ulink linkID="547198" linkType="reference"&gt;547198&lt;/ulink&gt;]. Similar data were presented at the 46th ASH meeting in San Diego, CA [&lt;ulink linkID="576672" linkType="Reference"&gt;576672&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, preclinical data were presented at the 95th AACR meeting in Orlando, FL. Dovitinib inhibited FGF-mediated growth of B9-WT and B9-TD cells with IC50 values of 25 and 80 nM, respectively, as determined by MTT assay. Growth of these cells could be rescued by IL-6, demonstrating selectivity of dovitinib for FGFR3. At concentrations that prevented cell growth, dovitinib inhibited in vitro FGFR3 autophosphorylation. Dovitinib inhibited the growth of FGFR3-expressing MM cell lines, namely KMS11 (Y373C), OPM2 (K650E), KMS18 (G384D) and H929 (WT FGFR3) cells with IC50 values of 100 nM (KMS11 and OPM2 cells), 250 nM and 630 nM, respectively. U266 cells, which lack FGFR3 expression, displayed minimal growth inhibition, demonstrating that at effective concentrations, dovitinib exhibits minimal nonspecific cytotoxicity on MM cells [&lt;ulink linkID="530608" linkType="reference"&gt;530608&lt;/ulink&gt;]. Similar data were presented in December 2004 at the 46th ASH meeting in San Diego, CA [&lt;ulink linkID="573953" linkType="Reference"&gt;573953&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2003, data were presented at the 15th AACR-&lt;ulink linkID="20519" linkType="Company"&gt;NCI&lt;/ulink&gt;-&lt;ulink linkID="23119" linkType="Company"&gt;EORTC&lt;/ulink&gt; meeting in Boston, MA. Dovitinib (IC50 for FLT3 = 0.1nM; VEGFR1/2, FGFR1/3 ~10 nM, PDGFR = 30 nM), was evaluated in the leukemic tumor cell lines MV4-11 (ITD mutant with constitutively active FLT3) and RS4 (FLT3 WT) in vitro and in vivo. In vitro, dovitinib inhibited proliferation, receptor phosphorylation and downstream signaling (STAT-5 and ERK/MAPK) of MV4-11 cells (GI50 or cell proliferation EC50 = 5 to 15 nM). This was also observed in RS4 cells (FLT3 WT; EC50 = 510 nM), but less than in the FLT3 ITD mutant MV4-11 cell line. Dovitinib was also tested in vivo in the sc MV4-11 AML tumor xenograft model in SCID-NOD mice. Oral dosing was initiated in mice with established tumors of 300, 500, or 1000 mm3. A dose-response effect was observed, with significant efficacy (ED50 approximately 4 mg/kg/day). Pharmacokinetic and pharmacodynamic relationships were also explored and inhibition of phosphorylation of downstream targets (ERK and STAT5) correlated with plasma and tumor exposure to dovitinib. Tumor responses were also independent of size of tumors at the start of treatment. Tumor regressions were observed with doses over 10 mg/kg/day, against established (300 mm3) and large tumors (500 or 1000 mm3). Responses were generally durable and most tumors remained stable even after cessation of dosing. Recurring tumors were responsive to a second cycle of 30 mg/kg/day, suggesting lack of acquired resistance of MV4-11 tumors to dovitinib. Alternate dose-scheduling studies showed efficacy comparable to that of daily dosing, supporting intermittent or cyclic dosing in clinical trials [&lt;ulink linkID="515035" linkType="reference"&gt;515035&lt;/ulink&gt;]. In December 2003, similar data were presented at the 45th ASH meeting in San Diego, CA [&lt;ulink linkID="515879" linkType="reference"&gt;515879&lt;/ulink&gt;]. Similar data were also presented in December 2004 at the 46th ASH meeting in San Diego, CA [&lt;ulink linkID="572706" linkType="Reference"&gt;572706&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003, preclinical data were presented at the 94th AACR Meeting, Washington, DC. Dovitinib was shown to exhibit potent inhibitory activity (IC50 = 10 to 25 nM) against selective growth factor receptor tyrosine kinases, VEGFR1, VEGFR2, FGFR and PDGFR. Dovitinib inhibited the proliferation of a subset of cancer cell lines, with EC50 values of less than 25 nM; three human cancer cell lines, MV4-11 (AML), TF-1 (AML) and KM12l4A (colon cancer), were identified to be at least 10-fold more sensitive to the antiproliferative effects of dovitinib than the other cell lines tested [&lt;ulink linkID="497736" linkType="reference"&gt;497736&lt;/ulink&gt;], [&lt;ulink linkID="497653" linkType="reference"&gt;497653&lt;/ulink&gt;]. In in vivo studies, human colon tumor (KM12L4a) xenografts treated with dovitinib (3, 10, 30, 60 or 100 mg/kg orally qd), demonstrated significant tumor regression and inhibition after four doses of greater than 330 mg/kg. In the same model of larger tumors (500 or 1000 mm3 compared to 125 mm3), regression and/or disease stabilization was observed in 90 to 100% of animals. In a mouse model of murine breast cancer (4T1), dovitinib (10, 30, 60, 100 or 150 mg/kg qd) inhibited primary tumor growth in a dose-dependent manner (20 to 82%) and liver metastases were inhibited by more than 75% at all doses greater than 10 mg/kg/day. In further studies, dovitinib was shown to potentiate the antitumor activity of the standard cytotoxic therapeutics &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt;, &lt;ulink linkID="6386" linkType="Drug"&gt;trastuzumab&lt;/ulink&gt;  and &lt;ulink linkID="11603" linkType="Drug"&gt;gefitinib&lt;/ulink&gt;  [&lt;ulink linkID="497740" linkType="reference"&gt;497740&lt;/ulink&gt;], [&lt;ulink linkID="497653" linkType="reference"&gt;497653&lt;/ulink&gt;]. Analysis of KM12L4a tumors after dovitinib treatment indicated that phosphorylation of VEGFR1, VEGFR2, PDGFRb and FGFR were inhibited in a time-and-dose-dependent manner. The inhibitory effect of dovitinib on receptor phosphorylation was maintained for 24 h after treatment [&lt;ulink linkID="497886" linkType="reference"&gt;497886&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Pharmacokinetics data were also presented in July 2003 at the 94th AACR Meeting, Washington, DC. The absolute oral bioavailability of dovitinib was greater than 70% in mice, rats and monkeys; and 34% in dogs. Maximum plasma and tissue concentrations occurred approximately 4 h following an oral dose in mice and rats. The elimination half-life ranged from 2.7 to 3.6 h in plasma following an iv dose [&lt;ulink linkID="496695" linkType="reference"&gt;496695&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2003, data were presented at the SMi's Kinases conference in London, UK. The compound had significant antitumor activity in more than 10 models, including the KM12L4A human colon tumor model. It was also reported to induce tumor regression in large tumors, and had potent anti-angiogenic activity in vitro and in vivo [&lt;ulink linkID="485989" linkType="reference"&gt;485989&lt;/ulink&gt;], [&lt;ulink linkID="486125" linkType="reference"&gt;486125&lt;/ulink&gt;]. Similar data were presented in July 2003, at the Fifth Annual Anticancer Drug Discovery &amp;amp; Development meeting in Philadelphia, PA [&lt;ulink linkID="501382" linkType="reference"&gt;501382&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Novartis (formerly Chiron) holds worldwide rights.&lt;/para&gt;&lt;para&gt;By June 2006, the company intended to file dovitinib jointly with a diagnostic that identifies and stratifies patients by FGF expression [&lt;ulink linkID="677135" linkType="Reference"&gt;677135&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The phase I trial in multiple myeloma, initiated in   June 2005,  was conducted through the Multiple Myeloma Research Consortium [&lt;ulink linkID="605481" linkType="Reference"&gt;605481&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1143038">OV-SPV2 ApS</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1766">Renal cell carcinoma</Indication><StatusDate>2018-01-15T00:00:00.000Z</StatusDate><Source id="1997350" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1143038">OV-SPV2 ApS</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="202">Liver tumor</Indication><StatusDate>2018-07-26T00:00:00.000Z</StatusDate><Source id="2057182" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1143038">OV-SPV2 ApS</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2018-01-15T00:00:00.000Z</StatusDate><Source id="1997350" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1143038">OV-SPV2 ApS</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2018-04-09T00:00:00.000Z</StatusDate><Source id="2020644" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1143038">OV-SPV2 ApS</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2019-04-30T00:00:00.000Z</StatusDate><Source id="2146834" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1143038">OV-SPV2 ApS</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2019-04-30T00:00:00.000Z</StatusDate><Source id="2146834" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3948">Inflammatory breast cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="989">Colorectal tumor</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2454">Glioblastoma</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3257">Stage IV melanoma</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1612">Hippel Lindau syndrome</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1240">Mesothelioma</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2380">Bladder cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2380">Bladder cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2380">Bladder cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1648">Adrenal cortical carcinoma</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3153">Adenoid tumor</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2380">Bladder cancer</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2012-12-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2013-07-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2013-07-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2013-07-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2014-02-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2013-07-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1766">Renal cell carcinoma</Indication><StatusDate>2013-07-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2012-12-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1766">Renal cell carcinoma</Indication><StatusDate>2018-04-09T00:00:00.000Z</StatusDate><Source id="2020644" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2018-04-09T00:00:00.000Z</StatusDate><Source id="2020644" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2009-02-27T00:00:00.000Z</StatusDate><Source id="992023" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2004-09-28T00:00:00.000Z</StatusDate><Source id="1353100" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2004-10-26T00:00:00.000Z</StatusDate><Source id="565808" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1612">Hippel Lindau syndrome</Indication><StatusDate>2010-12-22T00:00:00.000Z</StatusDate><Source id="1178215" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2004-10-31T00:00:00.000Z</StatusDate><Source id="565808" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2004-10-31T00:00:00.000Z</StatusDate><Source id="565808" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2012-03-12T00:00:00.000Z</StatusDate><Source id="1178464" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2011-11-22T00:00:00.000Z</StatusDate><Source id="1243285" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2001-06-13T00:00:00.000Z</StatusDate><Source id="413050" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1240">Mesothelioma</Indication><StatusDate>2013-01-09T00:00:00.000Z</StatusDate><Source id="1439473" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2011-03-16T00:00:00.000Z</StatusDate><Source id="1178876" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2011-03-16T00:00:00.000Z</StatusDate><Source id="1178876" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2011-03-16T00:00:00.000Z</StatusDate><Source id="1178876" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2008-07-31T00:00:00.000Z</StatusDate><Source id="1129301" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2011-03-16T00:00:00.000Z</StatusDate><Source id="1178876" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2011-04-30T00:00:00.000Z</StatusDate><Source id="1523877" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1240">Mesothelioma</Indication><StatusDate>2013-07-05T00:00:00.000Z</StatusDate><Source id="1439473" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-01-13T00:00:00.000Z</StatusDate><Source id="519079" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-05-28T00:00:00.000Z</StatusDate><Source id="1013444" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1612">Hippel Lindau syndrome</Indication><StatusDate>2012-11-13T00:00:00.000Z</StatusDate><Source id="1178215" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2011-08-10T00:00:00.000Z</StatusDate><Source id="1178464" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1129284" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2011-12-12T00:00:00.000Z</StatusDate><Source id="1230990" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-05-28T00:00:00.000Z</StatusDate><Source id="1013444" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-05-28T00:00:00.000Z</StatusDate><Source id="1013444" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2011-12-12T00:00:00.000Z</StatusDate><Source id="1230990" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2011-12-12T00:00:00.000Z</StatusDate><Source id="1230990" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2011-12-12T00:00:00.000Z</StatusDate><Source id="1230990" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-04-25T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-04-25T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-04-25T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-04-25T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2009-08-31T00:00:00.000Z</StatusDate><Source id="1129303" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2009-08-31T00:00:00.000Z</StatusDate><Source id="1129303" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate>2010-03-31T00:00:00.000Z</StatusDate><Source id="1129310" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate>2010-03-31T00:00:00.000Z</StatusDate><Source id="1129310" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate>2010-03-31T00:00:00.000Z</StatusDate><Source id="1129310" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate>2010-03-31T00:00:00.000Z</StatusDate><Source id="1129310" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2010-05-31T00:00:00.000Z</StatusDate><Source id="1178898" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2010-05-31T00:00:00.000Z</StatusDate><Source id="1178898" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2010-05-31T00:00:00.000Z</StatusDate><Source id="1178898" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2010-05-31T00:00:00.000Z</StatusDate><Source id="1178898" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2011-12-12T00:00:00.000Z</StatusDate><Source id="1230990" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2011-11-10T00:00:00.000Z</StatusDate><Source id="1241286" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3153">Adenoid tumor</Indication><StatusDate>2012-03-05T00:00:00.000Z</StatusDate><Source id="1261087" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2012-05-30T00:00:00.000Z</StatusDate><Source id="1243285" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate>2006-04-30T00:00:00.000Z</StatusDate><Source id="1263821" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2013-01-09T00:00:00.000Z</StatusDate><Source id="1178464" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2013-02-28T00:00:00.000Z</StatusDate><Source id="1440754" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2013-02-28T00:00:00.000Z</StatusDate><Source id="1440754" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1448594" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate>2012-10-31T00:00:00.000Z</StatusDate><Source id="1442057" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3948">Inflammatory breast cancer</Indication><StatusDate>2012-01-31T00:00:00.000Z</StatusDate><Source id="1441754" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1648">Adrenal cortical carcinoma</Indication><StatusDate>2011-12-11T00:00:00.000Z</StatusDate><Source id="1442637" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2010-09-21T00:00:00.000Z</StatusDate><Source id="1129303" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-04-25T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate>2012-06-30T00:00:00.000Z</StatusDate><Source id="1905409" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate><Source id="1636427" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-01-13T00:00:00.000Z</StatusDate><Source id="519079" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2006-04-19T00:00:00.000Z</StatusDate><Source id="662678" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2006-04-19T00:00:00.000Z</StatusDate><Source id="662678" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2008-07-31T00:00:00.000Z</StatusDate><Source id="1129301" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2008-07-31T00:00:00.000Z</StatusDate><Source id="1129301" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1095288">Oncology Venture ApS</OwnerCompany><Country id="US">US</Country><Indication id="3153">Adenoid tumor</Indication><AwardedIndication>Treatment of adenoid cystic carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2018-06-28T00:00:00.000Z</MileStoneDate><Source id="2049943" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="3153">Adenoid tumor</Indication><AwardedIndication>Treatment of adenoid cystic carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-09-26T00:00:00.000Z</MileStoneDate><Source id="1483437" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="1828">Multiple myeloma</Indication><AwardedIndication>Treatment of multiple myeloma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2006-10-03T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00510"><Name>CSF-1</Name><SwissprotNumbers><Swissprot>P07333</Swissprot><Swissprot>P09581</Swissprot><Swissprot>P13369</Swissprot><Swissprot>Q00495</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00736"><Name>FGF1 receptor</Name><SwissprotNumbers><Swissprot>P11362</Swissprot><Swissprot>P16092</Swissprot><Swissprot>Q04589</Swissprot><Swissprot>Q07407</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00737"><Name>FGF2 receptor</Name><SwissprotNumbers><Swissprot>P21802</Swissprot><Swissprot>P21803</Swissprot><Swissprot>Q09147</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00738"><Name>FGF3 receptor</Name><SwissprotNumbers><Swissprot>Q61851</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00762"><Name>Flt3 tyrosine kinase</Name><SwissprotNumbers><Swissprot>P36888</Swissprot><Swissprot>Q00342</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01208"><Name>Kit tyrosine kinase</Name><SwissprotNumbers><Swissprot>O97799</Swissprot><Swissprot>P05532</Swissprot><Swissprot>P10721</Swissprot><Swissprot>P43481</Swissprot><Swissprot>Q08156</Swissprot><Swissprot>Q28317</Swissprot><Swissprot>Q28889</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01531"><Name>PDGF receptor</Name><SwissprotNumbers/></Target><Target id="PTGT-01670"><Name>Ret tyrosine kinase receptor</Name><SwissprotNumbers><Swissprot>P07949</Swissprot><Swissprot>P35546</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01891"><Name>TrkA receptor</Name><SwissprotNumbers><Swissprot>P04629</Swissprot><Swissprot>P35739</Swissprot><Swissprot>Q91009</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01938"><Name>VEGF-1 receptor</Name><SwissprotNumbers><Swissprot>P17948</Swissprot><Swissprot>P35969</Swissprot><Swissprot>P53767</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01939"><Name>VEGF-2 receptor</Name><SwissprotNumbers><Swissprot>O08775</Swissprot><Swissprot>P35918</Swissprot><Swissprot>P35968</Swissprot><Swissprot>P52583</Swissprot><Swissprot>Q8AXB3</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01940"><Name>VEGF-3 receptor</Name><SwissprotNumbers><Swissprot>P35916</Swissprot><Swissprot>P35917</Swissprot></SwissprotNumbers></Target><Target id="PTGT-03992"><Name>SL cytokine ligand</Name><SwissprotNumbers><Swissprot>P49771</Swissprot><Swissprot>P49772</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2167486" linkType="reference" linkID="2167486"&gt;2167486&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1025145">Oncology Venture A/S</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1034106">Multiple Myeloma Research Consortium</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="20">Company - M&amp;A (in whole or part)</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC(C(=O)O)O.CN1CCN(CC1)c2ccc3c(c2)[nH]c(n3)c4c(c5c(cccc5F)[nH]c4=O)N</Smiles><Smiles>CC(C(=O)O)O.CN1CCN(CC1)c2ccc3c(c2)[nH]c(n3)c4c(c5c(cccc5F)[nH]c4=O)N.O</Smiles><Smiles>CN1CCN(CC1)c2ccc3c(c2)[nH]c(n3)c4c(c5c(cccc5F)[nH]c4=O)N</Smiles></StructureSmiles><Deals><Deal id="127567" title="Novartis to use the MMRC to conduct trials for dovitinib"/><Deal id="236714" title="Oncology Venture to spun out OV-SPV2 to develop an oral TKI inhibitor for cancer worldwide      "/><Deal id="241336" title="Oncology Venture to receive an option to develop and commercialize Novartis's undisclosed small molecule for multiple indications   "/></Deals><PatentFamilies><PatentFamily id="1071377" number="WO-2008013912" title="Use of melanoma inhibitory activity (MIA) protein as an early indicator for therapeutic response in melanoma"/><PatentFamily id="1186702" number="WO-2011128403" title="Organic compound for use in the treatment of liver cancer"/><PatentFamily id="1257048" number="WO-2011117380" title="Preparation of hydrated polymorphs of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salt"/><PatentFamily id="1366804" number="WO-2007067968" title="Effects of inhibitors of FGFR3 on gene transcription"/><PatentFamily id="1477939" number="WO-2009115562" title="Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts"/><PatentFamily id="1531590" number="WO-2008112509" title="Treatment of melanoma"/><PatentFamily id="1622036" number="WO-2006125130" title="Methods for synthesizing heterocyclic compounds"/><PatentFamily id="1631117" number="WO-2009086204" title="Methods for treating neuropsychiatric conditions"/><PatentFamily id="1693644" number="WO-03087095" title="Quinolinone derivatives"/><PatentFamily id="1860336" number="WO-2012125812" title="FGFR and ligands thereof as biomarkers for breast cancer in HR positive subjects"/><PatentFamily id="221351" number="WO-2010003078" title="Melt granulation process"/><PatentFamily id="2371187" number="WO-2012001074" title="Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactate monohydrate."/><PatentFamily id="2404224" number="WO-2012158994" title="4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one for use in the treatment of adenoid cystic carcinoma"/><PatentFamily id="2474321" number="WO-2005046589" title="Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties"/><PatentFamily id="2494356" number="WO-2013039764" title="Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients"/><PatentFamily id="2519685" number="WO-2013063000" title="Method of treating gastrointestinal stromal tumors"/><PatentFamily id="2564626" number="JP-05945863" title="Renal cancer therapeutic agent"/><PatentFamily id="2573063" number="WO-2013116293" title="Combination of a RTK inhibitor with an anti - estrogen and use thereof for the treatment of cancer"/><PatentFamily id="2590443" number="WO-2013133351" title="Novel FGFR3 fusion product"/><PatentFamily id="2627054" number="US-09254288" title="Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof"/><PatentFamily id="2666197" number="WO-2014011284" title="Method of treating gastrointestinal stromal tumors"/><PatentFamily id="2717390" number="WO-2014058785" title="Combination therapy"/><PatentFamily id="3166365" number="WO-2016055916" title="Therapeutic combination for the treatment of cancer"/><PatentFamily id="3175292" number="KR-2016040795" title="Composition comprising dovitinib useful for treating osteoporosis"/><PatentFamily id="3227003" number="WO-2016107778" title="C-19 steroids for inhibiting neovascularization"/><PatentFamily id="32457" number="WO-2006081445" title="Treatment of metastasized tumors"/><PatentFamily id="3278176" number="WO-2016126618" title="Combination therapies"/><PatentFamily id="3440375" number="WO-2016178881" title="Topical formulations and uses thereof"/><PatentFamily id="3683443" number="WO-2017100642" title="Methods for reducing or preventing growth of tumors resistant to EGFR and/or ERBB3 blockade"/><PatentFamily id="3706295" number="US-20170191131" title="Probes to fibronectin and fibroblast growth factor receptor genes"/><PatentFamily id="401895" number="WO-2005082340" title="Modulation of inflammatory and metastatic processes"/><PatentFamily id="445907" number="WO-2011053779" title="Methods for treating cancer in patients having IGF-1R inhibitor resistance"/><PatentFamily id="496727" number="WO-2006127926" title="Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts"/><PatentFamily id="567539" number="WO-2006124413" title="Methods for treating drug resistant cancer"/><PatentFamily id="68358" number="WO-2007064719" title="Formulations of quinolinones"/><PatentFamily id="769034" number="WO-00222598" title="Quinolinone derivatives"/><PatentFamily id="810662" number="US-08216783" title="Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors"/><PatentFamily id="890345" number="WO-2011128405" title="Combination of organic compounds"/><PatentFamily id="997578" number="WO-2008104523" title="A method of identification of cells that show sensitivity to modulation of signaling mediated by a fibroblast growth factor receptor or a variant thereof."/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>13</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>11</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kochi University" id="1012203"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Astellas Pharma Inc" id="1013295"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Translational Genomics Research Institute" id="1013832"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Centro Nacional de Investigaciones Oncologicas" id="1017946"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eulji University" id="1031573"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ActoKine Therapeutics" id="1032282"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Princess Margaret Hospital" id="1032985"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pathway Therapeutics Ltd" id="1040247"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Afraxis Inc" id="1048487"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Redx Pharma Plc" id="1060461"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Curadis GmbH" id="1062010"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Redag Crop Protection Ltd" id="1122298"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CytoTest Inc" id="1142158"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Destiny Life Sciences" id="1150675"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Denki Kagaku Kogyo Kabushiki Kaisha" id="15656"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Korea Research Institute of Chemical Technology" id="17684"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Regeneron Pharmaceuticals Inc" id="19214"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Queensland University of Technology" id="23070"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>27</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>27</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Texas A&amp;M University System" id="23290"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="UOP (Universal Oil Products) Inc" id="24831"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MEI Pharma Inc" id="28700"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>